BlackRock Updates Passive Stake in Ironwood Pharma (IRWD)
Ticker: IRWD · Form: SC 13G/A · Filed: Jan 22, 2024 · CIK: 1446847
| Field | Detail |
|---|---|
| Company | Ironwood Pharmaceuticals Inc (IRWD) |
| Form Type | SC 13G/A |
| Filed Date | Jan 22, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, amendment, pharmaceuticals
TL;DR
**BlackRock just updated its passive stake in Ironwood Pharma, signaling continued institutional interest.**
AI Summary
BlackRock, Inc. filed an amended SC 13G/A on January 22, 2024, indicating its ownership of Class A Common Stock in IRONWOOD PHARMACEUTICALS INC as of December 31, 2023. This filing, an amendment number 3, updates BlackRock's passive investment stake in Ironwood. This matters to investors because BlackRock is a major institutional investor, and changes in its holdings can signal its confidence (or lack thereof) in the company's future prospects, potentially influencing other investors.
Why It Matters
BlackRock's updated filing shows its continued, albeit passive, interest in Ironwood Pharmaceuticals, which can be a positive signal for current and prospective shareholders.
Risk Assessment
Risk Level: low — This filing is a routine update from a passive institutional investor and does not indicate any immediate significant risk or opportunity.
Analyst Insight
Investors should note BlackRock's continued passive interest, but this filing alone doesn't suggest a need for immediate action. It's a routine update confirming institutional presence.
Key Players & Entities
- BlackRock, Inc. (company) — the reporting person and institutional investor
- IRONWOOD PHARMACEUTICALS INC (company) — the subject company in which BlackRock holds shares
- December 31, 2023 (date) — the date of the event requiring the filing
- January 22, 2024 (date) — the filing date of the SC 13G/A amendment
- Amendment No: 3 (number) — indicates this is the third amendment to BlackRock's Schedule 13G for Ironwood
Forward-Looking Statements
- BlackRock will maintain a significant, passive stake in Ironwood Pharmaceuticals. (BlackRock, Inc.) — high confidence, target: Next 12 months
FAQ
What type of filing is this and what does it generally indicate?
This is an SC 13G/A filing, which is an amendment to a Schedule 13G. It indicates that a passive institutional investor, in this case BlackRock, Inc., is updating its ownership stake in a company, IRONWOOD PHARMACEUTICALS INC, as of a specific date (December 31, 2023).
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., a major asset management firm, as stated under 'Names of reporting persons. BlackRock, Inc.' in the filing.
What is the subject company of this filing?
The subject company is IRONWOOD PHARMACEUTICALS INC, as clearly stated under 'Name of Issuer' and 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: IRONWOOD PHARMACEUTICALS INC'.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as specified in the filing.
What rule is BlackRock filing under for this Schedule 13G?
BlackRock is filing under Rule 13d-1(b), indicated by '[X] Rule 13d-1(b)' in the filing, which is typically used by passive institutional investors.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 22, 2024 regarding IRONWOOD PHARMACEUTICALS INC (IRWD).